Search Site

Trends banner

‘Wadeem’ sold out for $1.49bn

This is the highest Abu Dhabi real-estate release to date.

Tesla Q2 sales down 13.5%

Shares rally after the disclosure, better than some forecasts.

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

GSK to buy Aiolos Bio

The purchase of Aiolos Bio, based in London and San Francisco, furthers GSK's push into its core drugmaking business. (AFP)
  • The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma
  • AIO-001 was exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals, which initially developed the asthma treatment

London, United Kingdom – British drugmaker GlaxoSmithKline on Tuesday agreed to buy Aiolos Bio for up to $1.4 billion, with focus on an asthma medication still at the testing stage.

The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma.

GSK said in a statement that the drug has the “potential to… reach a broader portion of asthma patients”.

AIO-001 was exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals, which initially developed the asthma treatment.

The purchase of Aiolos Bio, based in London and San Francisco, furthers GSK’s push into its core drugmaking business after the spinoff of consumer healthcare unit Haleon in 2022.

“We have a proud heritage and deep development expertise in respiratory medicines,” GSK’s chief scientific officer Tony Wood said in the statement.

“Adding AIO-001, a potentially best-in-class medicine… could expand the reach of our current respiratory biologics portfolio.”